# The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients

Study · id `cardio:ct-nct04728516` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04728516](<https://clinicaltrials.gov/study/NCT04728516>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04728516

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2600 participants.

## Technical summary

Registry record NCT04728516. Randomized; no masking; primary purpose prevention. Start 2023-04-12 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 2600 participants (planned count; ClinicalTrials.gov record NCT04728516, source copy `cardio:ctgov-nct04728516-2025-09-16`, retrieved 2026-10-31)
- Started: 2023-04-12 (actual) (ClinicalTrials.gov record NCT04728516, source copy `cardio:ctgov-nct04728516-2025-09-16`, retrieved 2026-10-31)
- Primary completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT04728516, source copy `cardio:ctgov-nct04728516-2025-09-16`, retrieved 2026-10-31)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT04728516, source copy `cardio:ctgov-nct04728516-2025-09-16`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04728516, source copy `cardio:ctgov-nct04728516-2025-09-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04728516-2025-09-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
- Condition: Acute Coronary Syndrome
- Condition: Helicobacter Pylori Infection
- Intervention (Drug): Vonoprazan-based dual eradication therapy for two weeks
- Intervention (Drug): amoxicillin
- Intervention (Drug): Pantoprazole
- Lead sponsor: Qilu Hospital of Shandong University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Qilu Hospital of Shandong University (`cardio:org-qilu-hospital-of-shandong-university`)

## Provenance

Content hash: 17fee9cd5c067757a8a2e864d72c9728242727e01ec37a2928f9b3eaa9b1bede
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
